These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 3082830

  • 1. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 2. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 3. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 4. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [Abstract] [Full Text] [Related]

  • 5. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T.
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [Abstract] [Full Text] [Related]

  • 6. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 7. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 8. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 10. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 11. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J, Yoshioka T, Kosugi A, Ogata M, Fujiwara H, Hamaoka T, Ueda S, Kato S.
    Biken J; 1987 Mar 01; 30(1):1-8. PubMed ID: 2445335
    [Abstract] [Full Text] [Related]

  • 12. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K, Fujiwara H, Nakajima H, Yoshioka T, Takai Y, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov 01; 77(11):1142-52. PubMed ID: 3098724
    [Abstract] [Full Text] [Related]

  • 13. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 14. Distinct subsets of accessory cells activate Thy-1+ triple negative (CD3-, CD4-, CD8-) cells and Th-1 delayed-type hypersensitivity effector T cells.
    Matsushima GK, Stohlman SA.
    J Immunol; 1991 May 15; 146(10):3322-31. PubMed ID: 1673982
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of passive antilisterial immunity and change of Lyt phenotype following in vitro stimulation of murine lymphoid cells from immune donors.
    Barry RA, Hinrichs DJ.
    Clin Invest Med; 1984 May 15; 7(4):303-9. PubMed ID: 6442653
    [Abstract] [Full Text] [Related]

  • 16. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 17. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar 15; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 18. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1986 Mar 15; 21(3):193-8. PubMed ID: 2938736
    [Abstract] [Full Text] [Related]

  • 19. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Eur J Immunol; 1988 Nov 15; 18(11):1773-8. PubMed ID: 2974424
    [Abstract] [Full Text] [Related]

  • 20. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
    Okada T, Ezawa K, Imai Y, Osawa T.
    Cancer Res; 1986 Nov 15; 46(11):5611-7. PubMed ID: 3093067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.